원클릭으로 Manus에서 모든 스킬 실행

ata-aed-ai-education

스타5

포크1

업데이트2026년 6월 27일 01:34

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

설치

Codex 또는 Claude로 설치 이 Prompt를 복사해 Codex, Claude 또는 다른 어시스턴트에 붙여 넣으면 Skill 페이지를 검토하고 설치를 진행할 수 있습니다.

Manus에서 실행

출처

dromlakhani

dromlakhani/MD2SKILL

GitHub 저장소 열기 Creator 저장소 보기

다운로드

Manus에서 실행

Educate adrenal insufficiency patients on enzyme-inducing antiepileptic drugs about early AI signs

STEP 1 — Gather Information

Confirm adrenal insufficiency diagnosis, verify current glucocorticoid regimen (nondexamethasone), identify newly prescribed enzyme-inducing AED, assess baseline symptoms.
Action: If patient meets criteria, proceed to Step 2.

STEP 2 — Rule In / Rule Out

Determine if the patient is on nondexamethasone GC and has started an enzyme-inducing AED (e.g., phenytoin, carbamazepine, oxcarbazepine, phenobarbital, primidone).
Action: If yes, proceed to Step 3; if no, no further education needed.

STEP 3 — Classify or Stratify

Assess baseline cortisol replacement adequacy and recent symptoms; classify as stable AI patient requiring education on early AI signs.
Action: Proceed to structured patient education.

STEP 4 — Decide

Provide education on early AI signs (fatigue, weakness, nausea/vomiting, abdominal pain, hypotension, hyponatremia, hypoglycemia) and instruct patient to contact clinician or seek emergency care if symptoms develop; review stress-dose guidelines.
Action: Document education and schedule follow-up.

Clinical Guardrails / Mimics / Pitfalls

Do not delay education until symptoms appear; do not assume patient recognizes subtle signs; do not overlook drug interactions that may reduce glucocorticoid efficacy; do not forget to advise about emergency injectable glucocorticoid kit.

Concrete Clinical Example

A 34-year-old woman with secondary AI on hydrocortisone 15 mg AM/5 mg PM starts carbamazepine for focal seizures; clinician educates her about early AI signs; two weeks later she reports mild nausea and fatigue, contacts clinic, receives stress-dose hydrocortisone, avoids adrenal crisis.

Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, 10.1210/jc.2016-2118

이 저장소의 다른 Skills

같은 저장소

genryzon-drug-interactions

dromlakhani/MD2SKILL

Drug-interaction and co-medication adjustment reference for a child on Genryzon (somatrogon, weekly long-acting growth hormone). Covers glucocorticoids, insulin and oral hypoglycaemics, thyroxine, oral estrogen, and CYP3A4-metabolised drugs (sex steroids, corticosteroids, anticonvulsants, ciclosporin). Use when a clinician asks about drug interactions with Genryzon or somatrogon, prescribing another drug in a child on GH, girl on Genryzon starting OCP, diabetic child starting GH, adjusting hydrocortisone on GH, or CYP3A4 concerns with somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-igf1-titration

dromlakhani/MD2SKILL

Titrate Genryzon (somatrogon, weekly long-acting growth hormone) dose in a paediatric GHD patient using serum IGF-1 SDS. Encodes the mandatory 4-days-post-dose sampling rule, the target SDS window, the 15% dose-reduction trigger, and the oral estrogen adjustment. Use when a clinician asks how to titrate somatrogon, when to sample IGF-1 on Genryzon, target IGF-1 SDS on weekly GH, what to do if IGF-1 is too high on somatrogon, IGF-1 rising on Genryzon, how to adjust GH dose in a girl started on oral OCP, or presents a paediatric GHD case on somatrogon with an IGF-1 value to interpret. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-prescribing-guide

dromlakhani/MD2SKILL

Bedside prescribing reference for Genryzon (somatrogon, Pfizer India) — the once-weekly long-acting growth hormone for paediatric growth hormone deficiency. Use when a clinician asks how to start Genryzon, how to dose somatrogon in a child, how to switch a child from daily growth hormone to weekly somatrogon, how to inject the Genryzon pen, missed-dose rule for somatrogon, when to stop somatrogon, or needs a monograph-level prescribing decision for a paediatric GHD patient. Applies to children and adolescents ≥3 years of age. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-pretreatment-screening

dromlakhani/MD2SKILL

Pretreatment screening checklist before starting Genryzon (somatrogon, weekly long-acting growth hormone) in a child with confirmed paediatric growth hormone deficiency. Ensures thyroid, adrenal, glucose, ocular, tumour, and Prader-Willi status are checked before the first dose to prevent adrenal crisis, wasted therapy, unmasked hypothyroidism, unrecognised hyperglycaemia, missed intracranial hypertension, or sudden death in PWS. Use when a clinician asks what to check before starting somatrogon, workup before Genryzon, baseline tests for weekly GH, screening for adrenal insufficiency before GH, or is about to prescribe Genryzon in a paediatric GHD case. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-red-flag-monitoring

dromlakhani/MD2SKILL

Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

genryzon-treatment-discontinuation

dromlakhani/MD2SKILL

Decide when to stop Genryzon (somatrogon, weekly long-acting growth hormone) in a paediatric GHD patient — the three physiological gates (epiphyseal closure, height velocity <2 cm/year, bone age >14 in girls or >16 in boys) plus the safety-driven stops (active tumour, adult GHD re-evaluation, adverse events). Use when a clinician asks when to stop somatrogon, when to discontinue Genryzon, is the child done with GH, has this child reached final height on GH, transitioning GH from paediatric to adult care, or is reviewing a teenager who has been on Genryzon for years. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166).

2026-07-165

name	ata-aed-ai-education
description	Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

Educate adrenal insufficiency patients on enzyme-inducing antiepileptic drugs about early AI signs

STEP 1 — Gather Information

STEP 2 — Rule In / Rule Out

STEP 3 — Classify or Stratify

Assess baseline cortisol replacement adequacy and recent symptoms; classify as stable AI patient requiring education on early AI signs.
Action: Proceed to structured patient education.

STEP 4 — Decide

Clinical Guardrails / Mimics / Pitfalls

Concrete Clinical Example

Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, 10.1210/jc.2016-2118